Lakshmi Chandrasekaran

Lakshmi Chandrasekaran

Auto-generated profile, based on publicly available information

Lakshmi Chandrasekaran

Walter Reed Army Institute of Research, Department of Diarrheal Disease Research, Bacterial Disease Branch, Silver Spring, MD 20910, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2020 in mSphere
Verified
Journal Article
Open access
PDF file
RJRobert W Frenck Jr
Robert W Frenck Jr
MDMichelle Dickey
Michelle Dickey
ASAkamol E. Suvarnapunya
Akamol E. Suvarnapunya
LCLakshmi Chandrasekaran
Lakshmi Chandrasekaran
RKRobert Kaminski
Robert Kaminski
CPChad Kiser Porter
Chad Kiser Porter
Controlled human infection models (CHIMs) are invaluable tools utilized to understand the human response to infection, potentially leading to protective immune mechanisms and allowing efficacy testing of enteric countermeasures, including vaccines, antibiotics, and other products. The development of an improved Shigella CHIM for both Shigella sonnei and Shigella flexneri is consistent with international efforts, supported by international donors and the World Health Organization, focused on standardizing Shigella CHIMs and using them to accelerate Shigella vaccine development. The use of lyophilized Shigella challenge strains rather than plate-grown inoculum preparations is considered an important step forward in the standardization process. Furthermore, the results of studies such as this justify the development of lyophilized preparations for additional epidemiologically important S. flexneri serotypes, including S. flexneri 3a and S. flexneri 6.

12 February 2025 in Vaccine
Verified
Journal Article
Open access
MSMatthew E. Sherman
Matthew E. Sherman
JMJane Michalski
Jane Michalski
SDSayan Das
Sayan Das
HYHyojik Yang
Hyojik Yang
LCLakshmi Chandrasekaran
Lakshmi Chandrasekaran
RERobert Ernst
Robert Ernst
Shigella spp. infection contributes significantly to the global disease burden, primarily affecting young children in developing countries. Currently, there are no FDA-approved vaccines against Shigella, and the prevalence of antibiotic resistance is increasing, making therapeutic options limited. Live-attenuated vaccine strains WRSs2 (S. sonnei) and WRSf2G12 (S. flexneri 2a) are highly immunogenic, making them promising vaccine candidates, but possess an inflammatory lipid A structure on their lipopolysaccharide (LPS; also known as endotoxin). Here, we utilized bacterial enzymatic combinatorial chemistry (BECC) to ectopically express lipid A modifying enzymes in WRSs2 and WRSf2G12, as well as their respective wild-type strains, generating targeted lipid A modifications across the Shigella backgrounds. Dephosphorylation of lipid A, rather than deacylation, reduced LPS-induced TLR4 signaling in vitro and dampened endotoxic effects in vivo. These BECC-modified vaccine strains retained the phenotypic traits of their parental strains, such as invasion of epithelial cells and immunogenicity in mice without adverse endotoxicity. Overall, our observations suggest that BECC-engineered live attenuated vaccines are a promising approach to safe and effective Shigella vaccines.